logo
Share SHARE
FONT-SIZE Plus   Neg

Icon Bioscience Names David Tierney President & CEO - Quick Facts

Icon Bioscience Inc., a privately held specialty biopharmaceutical company focused on the development and commercialization of unique ophthalmic pharmaceuticals based on its patented and proprietary Verisome drug delivery technology, said that David Tierney joined the Company as President & Chief Executive Officer.

Previously, Tierney served as President & COO of Oceana Therapeutics, Inc., a specialty therapeutic company he co-founded in mid-2008. Oceana quickly established a global commercial network and by December 2011 was acquired by Salix Pharmaceuticals (SLXP).

In 2000, David was appointed President & CEO of Hydro Med Sciences (HMS), a research firm with a promising drug delivery platform. Under his leadership, HMS emerged as Valera Pharmaceuticals, a fully integrated, commercial, specialty pharma company that successfully completed an initial public offering in 2005. Valera has since been merged into Endo Pharmaceuticals (ENDP). Prior to Valera, Tierney was President of Biovail Technologies, a drug delivery division of Biovail Corporation - a predecessor to Valeant Pharmaceuticals International (VRX). Earlier in his career, he served as Senior VP, Drug Development at Roberts Pharmaceutical and in a variety of management positions at Elan Corporation.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Internet access is growing worldwide, but there is still a long way to go before the entire world is completely wired, a study from the Pew Research Center has found. The study also noted that men have greater access to the Internet than women in many nations. Backtracking on its early announcements on digital privacy, WhatsApp is planning to share member information, phone numbers and analytical data with Facebook, to make revenue from the platform. Discount retailers Dollar Tree Inc. and Dollar General Corp. both reported results for the second quarter that missed analysts' expectations. Looking ahead, Dollar Tree also forecast revenue for the third quarter below analysts' estimates and lowered its full-year revenue outlook. Shares of both companies are falling in pre-market activity.
comments powered by Disqus
Follow RTT